Capecitabine plus docetaxel combination therapy: Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma

Cancer

Volumn 103, Issue 12, 2005, Pages 2455-2465

  Verma, Shailendra ^a   Maraninchi, Dominique ^b   O'Shaughnessy, Joyce ^c,d   Jamieson, Carol ^e   Jones, Stephen ^c,d   Martín, Miguel ^f   McKendrick, Joseph ^g   Miles, David ^h   Twelves, Chris ⁱ   Hornberger, John ^j,k,l  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b INSTITUT PAOLI CALMETTES   (France)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g BOX HILL HOSPITAL   (Australia)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^j Acumen LLC   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Capecitabine; Cost; Cost benefit; Docetaxel; Metastatic breast carcinoma; Pharmaco economics

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 20444389366     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21122     Document Type: Article

References (22)

1. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
2. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs. 2004; Web Exclusive. Available from URL: http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w4.284 [accessed May 19, 2004].
3. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996;276:1339-1341.
4. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
5. Sonnenberg FA, Beck IR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13: 322-338.
6. World Health Organization. World Health Organization handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
7. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493.
8. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1337-1345.
9. Miller RG Jr. Survival analysis. Wiley series in probability and mathematical statistics: applied probability and statistics. New York: John Wiley & Sons, Inc., 1981.
10. Red Book™ for Windows®. Greenwood, Co: Thomson Micromedex, 2003.
11. Hospital statistics 2001. American Hospital Association. Available from URL: http://www.ahaonlinestore.com [accessed date, year].
12. Mutual of Omaha. Current trends in health care and dental costs utilization. Available from URL: http://www.mutualofomaha.com/acrodocs/mugc6794. pdf [accessed May 5, 2005].
13. Healthcare Cost and Utilization Project (HCUPnet). Agency for healthcare research and quality. Available from URL: http://www.ahrq.gov/HCUPnet/ [accessed May 5, 2005].
14. Brown RE, Hutton J. Cost utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs. 1998;9:899-907.
15. Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996;10:504-521.
16. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics. 1996;9(Suppl 2):8-22.
17. Medicode national fee analyzer. Salt Lake City: Ingenix, 2001.
18. Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
19. @Risk. Version 4.5.1. Newfield, NY: Palisade Corporation.
20. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18:3302-3317.
21. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31.
22. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? JAMA. 2003;163:1637-1641.